Alzamend Neuro updates investor presentation for April 2023; no material new disclosures

Alzamend Neuro, Inc.

Company furnished an updated corporate presentation (Exhibit 99.1) used for investor meetings.
Presentation provides overview of therapeutic drugs for Alzheimer's and other neurodegenerative diseases.
Information furnished under Regulation FD; not deemed filed for SEC or incorporated by reference.
No specific pipeline updates, financial data, or clinical milestones disclosed with this filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.